ASHLEY BURNS: Open Payments
NPI 1710617261 · GILBERT, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$652 in 18 payments from 12 companies in 2025. Trend: 2023 $853 · 2024 $1,980 · 2025 $652
Food & beverage: $620Education: $32
| Company | Payments | Amount |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 2 | $155 |
| Ipsen Biopharmaceuticals, Inc | 1 | $125 |
| GENZYME CORPORATION | 2 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $52 |
| Ardelyx, Inc. | 2 | $48 |
| Janssen Biotech, Inc. | 2 | $45 |
| Madrigal Pharmaceuticals | 2 | $44 |
| Gilead Sciences, Inc. | 1 | $31 |
| QOL Medical, LLC | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
Products named: VOQUEZNA, IQIRVO, DUPIXENT, IBSRELA, TREMFYA, REZDIFFRA, Sucraid, XIFAXAN.
Industry payments across AZ — which companies pay providers there.
